Feed / QTTB

Q32 Bio Inc.

QTTB

Healthcare · 11.11 +3.5% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

Q32 Bio Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Company+3.5% todayVolume comparison unavailable
Market group0 of 18 activeBiotech and Energy · unavailable
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
  • QTTB's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if QTTB's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • QTTB's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods8
Price observations320
Usable filing statements83
Verified relationships3
Evidence supporting the case

No qualifying supportive evidence was identified.

Evidence challenging the case
  • Diluted shares increased 27.5% in the latest annual period.
  • Operating cash flow was only -1.125x net income in the latest annual period.
  • Product pipeline and R&D has repeated adverse evidence across 4 filings.
  • Restructuring and cost reductions has repeated adverse evidence across 4 filings.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 11, 2026

11.11
6m+124.3%12m+527.4%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$34.0M+1157.3%$-1.73
2022-12-31$3.2M-90.6%$-0.09+3.8%
2023-12-31−$6.7M-307.3%$-153.96
2024-12-31$0-100.0%$-6.58
2025-12-31$53.7M$2.42+27.5%

What management says matters

Persistent and emerging business drivers

Product pipeline and R&Dnegative · 4 filings
If the BMS Agreement is terminated for the Company’s material breach, BMS will regain rights to bempikibart and the Company must grant BMS an exclusive license under the Company’s patent rights covering bempikibart, subject to a low single digit percentage ro…
10-Q · May 5, 2026
Restructuring and cost reductionsnegative · 4 filings
The decrease in personnel-related and consultant costs was primarily related to lower headcount as compared to the prior year resulting from the corporate restructuring in February 2025.
10-Q · May 5, 2026
Credit and interest ratesmixed · 3 filings
These amounts are partially offset by interest expense of $1.1 million on our venture debt and an other-than-temporary impairment charge of approximately $0.7 million we recorded because it was determined that the fair value of our equity investment in OXB (U…
10-K · Mar 10, 2026

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

11.11+3.5% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for QTTB. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for QTTB. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind QTTB

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AKBAAkebia Therapeutics, Inc.partnerMar 10, 2026

On November 28, 2025, in connection with the ADX-097 Asset Sale, the Colorado License Agreement (defined in Note 10) was amended and restated and all of the Company’s rights and obligations thereunder were transferred to Akebia.

BMYBristol-Myers Squibb CompanypartnerMar 10, 2026

In particular, we depend substantially on our license agreement with Bristol Myers Squibb Company (“BMS”), under which we in-license patent rights and know-how that cover bempikibart (the “BMS Agreement”), and The Regents of the University of Colorado (the “C…

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

QTTB is currently a Follower in the organic co-movement group Biotech and Energy. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for QTTB; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.